STAT+: Pharmalittle: We’re Reading About FDA Seeking New Powers over DTC Ads, an EU Pledge to Fight AMR, and More

Why It Matters

The Shah Capital push could reshape Novavax’s governance and financial strategy, while the FDA’s proposed powers aim to protect consumers and curb deceptive marketing across the pharmaceutical sector.

Key Takeaways

• Shah Capital owns 9% of Novavax, votes against board re‑election
• Investor urges cost cuts and 10‑20 million share buyback
• Novavax may seek strategic partner holding 10‑20% stake
• FDA proposes new authority to curb misleading DTC drug ads
• Rule is part of FDA 2027 budget, targeting major pharma

Pulse Analysis

Activist investors are increasingly targeting mid‑stage biotech firms, and Shah Capital’s campaign against Novavax exemplifies this trend. Holding a 9% stake, the hedge fund argues that the vaccine maker’s cost structure remains too high and that a disciplined share‑repurchase program—targeting 10 million to 20 million shares—could unlock value for shareholders. By opposing board re‑elections and the current compensation package, Shah signals a willingness to force governance changes, potentially paving the way for a strategic partner willing to acquire a 10%‑20% equity position. Such activism can accelerate restructuring or even trigger a sale, reshaping the competitive landscape for COVID‑19 and other vaccine developers.

At the same time, the U.S. Food and Drug Administration is moving to tighten its grip on direct‑to‑consumer (DTC) drug advertising. The agency’s 2027 budget request includes authority to impose penalties on companies that present unbalanced risk‑benefit information, a response to a surge in misleading ads from major players like Bristol Myers Squibb, Eli Lilly and Novartis. By seeking legislative teeth, the FDA aims to restore consumer confidence and ensure that advertising reflects the rigorous safety standards required for prescription medicines. This regulatory push follows a series of warning letters and reflects broader political pressure to protect patients from deceptive marketing.

Together, these developments underscore a shifting paradigm for the pharmaceutical industry. Shareholder activism forces companies to prioritize cost efficiency and strategic clarity, while heightened regulatory scrutiny demands greater transparency in marketing. Investors and executives must now balance the pursuit of growth with the need to meet tighter governance standards and comply with evolving advertising rules. Companies that adapt quickly may gain a competitive edge, whereas those lagging could face shareholder revolts, regulatory penalties, or eroding brand trust in an increasingly consumer‑aware market.